Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022

被引:4
|
作者
van Iersel, Senna C. J. L. [1 ]
McDonald, Scott A. [1 ]
de Gier, Brechje [1 ]
Knol, Mirjam J. [1 ]
de Melker, Hester E. [1 ]
van Werkhoven, C. H. Henri [1 ,2 ]
Hahne, Susan J. M. [1 ]
机构
[1] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands
[2] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
关键词
COVID-19; SARS-CoV-2; Vaccination; Vaccine effectiveness;
D O I
10.1016/j.vaccine.2023.05.018
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Vaccines against COVID-19 have proven effective in preventing COVID-19 hospitalisation. In this study, we aimed to quantify part of the public health impact of COVID-19 vaccination by estimating the number of averted hospitalisations. We present results from the beginning of the vaccination campaign ('entire period', January 6, 2021) and a subperiod starting at August 2, 2021 ('subperiod') when all adults had the opportunity to complete their primary series, both until August 30, 2022.Methods: Using calendar-time specific vaccine effectiveness (VE) estimates and vaccine coverage (VC) by round (primary series, first booster and second booster) and the observed number of COVID-19 associated hospitalisations, we estimated the number of averted hospitalisations per age group for the two study periods. From January 25, 2022, when registration of the indication of hospitalisation started, hospitalisations not causally related to COVID-19 were excluded.Results: In the entire period, an estimated 98,170 (95 % confidence interval (CI) 96,123-99,928) hospitalisations were averted, of which 90,753 (95 % CI 88,790-92,531) were in the subperiod, representing 57.0 % and 67.9 % of all estimated hospital admissions. Estimated averted hospitalisations were lowest for 12-49-year-olds and highest for 70-79-year-olds. More admissions were averted in the Delta period (72.3 %) than in the Omicron period (63.4 %).Conclusion: COVID-19 vaccination prevented a large number of hospitalisations. Although the counterfactual of having had no vaccinations while maintaining the same public health measures is unrealistic, these findings underline the public health importance of the vaccination campaign to policy makers and the public.& COPY; 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:3847 / 3854
页数:8
相关论文
共 50 条
  • [41] COVID-19 Vaccination Improved Outcomes in the Treatment of Geriatric Hip Fractures Between December 2020 and January 2022
    Konda, Sanjit R.
    Meltzer Bruhn, Ariana T.
    Esper, Garrett W.
    Solasz, Sara J.
    Ganta, Abhishek
    Egol, Kenneth A.
    HIP INTERNATIONAL, 2023, 33 (06) : 1133 - 1139
  • [42] This Month in JAAD International: August 2022: Cutaneous reactions to COVID-19 messenger RNA booster dose vaccination
    Kantor, Jonathan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (02) : 205 - 205
  • [43] COVID-19 Vaccine for Children: Determinants and Beliefs Contributing to Vaccination Decision of Parents in Germany 2021/2022
    Purrmann, Laura
    Speichert, Leoni-Johanna
    Baeuerle, Alexander
    Teufel, Martin
    Krakowczyk, Julia Barbara
    Beckord, Jil
    Felderhoff-Mueser, Ursula
    Skoda, Eva-Maria
    Dinse, Hannah
    VACCINES, 2024, 12 (01)
  • [44] Impact of the COVID-19 pandemic on prevalence of highly resistant microorganisms in hospitalised patients in the Netherlands, March 2020 to August 2022
    Altorf-van der Kuil, Wieke
    Wielders, Cornelia C. H.
    Zwittink, Romy D.
    de Greeff, Sabine C.
    Dongelmans, Dave A.
    Kuijper, Ed J.
    Notermans, Daan W.
    Schoffelen, Annelot F.
    EUROSURVEILLANCE, 2023, 28 (50)
  • [45] Usage and Awareness of Antiviral Medications for Coronavirus Disease 2019 (COVID-19) Among Individuals at Risk for Severe COVID-19, March 2021 to 1 August 2022
    Kojima, Noah
    Klausner, Jeffrey D.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (04) : 775 - 776
  • [46] Investigating the Marginal and Herd Effects of COVID-19 Vaccination for Reducing Case Fatality Rate: Evidence from the United States between March 2021 to January 2022
    Li, Tenglong
    Wang, Zilong
    He, Shuyue
    Chen, Ying
    VACCINES, 2023, 11 (06)
  • [47] Excess deaths from COVID-19 in Japan and 47 prefectures from January through June 2021
    Nomura, S.
    Eguchi, A.
    Tanoue, Y.
    Yoneoka, D.
    Kawashima, T.
    Suzuki, M.
    Hashizume, M.
    PUBLIC HEALTH, 2022, 203 : 15 - 18
  • [48] Factors associated with the development, severity, and resolution of post COVID-19 condition in adults living in Canada, January 2020 to August 2022
    Zakaria, Dianne
    Demers, Alain
    Cheta, Nicholas
    Aziz, Samina
    Abdullah, Peri
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2024,
  • [49] Changes in COVID-19 vaccination receipt and intention to vaccinate by socioeconomic characteristics and geographic area, United States, January 6-March 29, 2021
    Nguyen, Kimberly H.
    Nguyen, Kimchi
    Corlin, Laura
    Allen, Jennifer D.
    Chung, Mei
    ANNALS OF MEDICINE, 2021, 53 (01) : 1419 - 1428
  • [50] Rare cases of Guillain-Barre syndrome after COVID-19 vaccination, Germany, December 2020 to August 2021
    Lehmann, Helmar C.
    Oberle, Doris
    Keller-Stanislawski, Brigitte
    Rieck, Thorsten
    Streit, Renz
    EUROSURVEILLANCE, 2023, 28 (24)